The management of painful crisis in sickle cell disease

Current Opinion in Supportive and Palliative Care

Volumn 4, Issue 2, 2010, Pages 97-106

  Wright, Josh ^a   Ahmedzai, Sam H ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Analgesia; Pain; Painful crisis; Sickle cell disease

Indexed keywords

NARCOTIC ANALGESIC AGENT;

HUMAN; PAIN; PAIN CLINIC; PALLIATIVE THERAPY; PATHOPHYSIOLOGY; REVIEW; SICKLE CELL ANEMIA;

ANALGESICS, OPIOID; ANEMIA, SICKLE CELL; HUMANS; PAIN; PAIN CLINICS; PALLIATIVE CARE;

EID: 77953852861     PISSN: 17514258     EISSN: 17514266     Source Type: Journal    
DOI: 10.1097/SPC.0b013e328339429a     Document Type: Review

References (64)

1. Pauling L, Itano HA, Singer JJ, Wells IC. Sickle cell anaemia, a molecular disease. Science 1949; 110:543-548.
2. Ingram. A specific chemical difference between globulins of normal haemoglobin and sickle cell anaemia haemoglobin. Nature 1956; 178: 792-794.
3. Serjeant GR, Serjeant BE, Stephens S, et al. Determinants of haemoglobin level in steady state homozygous sickle cell disease. Br J Haem 1996; 92:143-149.
4. Reiter CD, Wang X, Tanus Santos J, et al. Cell free haemoglobin limits nitric oxide availability in sickle cell disease. Nature Med 2002; 8:1383-1389.
5. Morris CR. Mechanisms of vasculopathy in sickle cell disease and thalassemia. Hematol Am Soc Hematol Edu Prog 2008:177-185.
6. Kato GJ, Hebbel RP, Steinberg MH, Gladwin MT. Vasculopathy in sickle cell disease: biology, pathophysiology, genetics, translational medicine and new research directions. Am J Hematol 2009; 84:618-625.
7. Van Zanten TEG, Statius Van Eps LW, Golding RP, Walk J. Imaging the bone marrow with magnetic resonance during a crisis and in chronic forms of sickle cell disease. Clin Radiol 1989; 40:486-489.
8. Singhal A, Doherty JF, Raynes JG, et al. Is there an acute phase response in steady state sickle disease? Lancet 1993; 341:651-653.
9. Stuart J, Stone PCW, Akinda NO, et al. Monitoring the acute phase response to vaso-occlusive crisis in sickle cell disease. J Clin Path 1994; 47:166-169.
10. Krishnan S, Setty Y, Betal SG, et al. Increased levels of the inflammatory biomarker C-reactive protein at baseline are associated with childhood sickle cell vaso-occlusive crises. Br J Haematol 2009. [Epub ahead of print]
11. Niscola P, Sorrentino F, Scaramucci L, et al. Pain syndromes in sickle cell disease: an update. Pain Med 2009; 10:470-480.
12. McClish DK, Smith WR, Dahman BA, et al. Pain site frequency and location in sickle cell disease: the PiSCES project. Pain 2009; 145:246-251.
13. McClish DK, Levenson JL, Penberthy LT, et al. Gender differences in pain and healthcare utilisation for adult sickle cell patients: the PiSCES project. J Women's Health 2006; 15:146-154.
14. Serjeant GR, De Ceular C, Lethbridge R, et al. The painful crisis of homozygous sickle cell disease: clinical features. Br J Haem 1994; 87:586-591.
15. Redwood AM, Williams EM, Desai RP, Serjeant GR. Climate and painful crisis of sickle cell disease in Jamaica. Br Med J 1976; 1:66-68.
16. Jones S, Duncan ER, Thomas N, et al. Windy weather and low humidity are associated with an increased number of hospital admissions for acute pain and sickle cell disease in an urban environment with a maritime temperate climate. Br J Haem 2005; 131:530-533.
17. Weirenga KJ, Hambleton IR, Wilson RM, et al. Significance of fever in Jamaican patients with homozygous sickle cell disease. Arch Dis Child 2001; 84:156-159.
18. Wright J, Thomas P, Serjeant GR. Septicaemia caused by salmonella infection; an overlooked complication of sickle cell disease. J Pediatr 1997; 130:394-399.
19. van Tits LJ, van Heerde WL, Landburg PP, et al. Plasma annexin A5 and microparticle phosphatidylserine levels are elevated in sickle cell disease and increase further during painful crisis. Biochem Biophys Res Communic 2009; 390:161-164.
20. Ennis JT, Serjeant GR, Middlemiss JH. Homozygous sickle cell disease in Jamaica. Br J Radiol 1973; 46:943-950.
21. Holdcroft A, Power I. Recent developments: management of pain. Br Med J 2003; 326:635-639.
22. Reichling DB, Levine JD. Critical role of nociceptor plasticity in chronic pain. Trends Neurosci 2009; 32:611-618.
23. Xiao HS, Huang QH, Zhang FX, et al. Identification of gene expression profile of dorsal root ganglion in the rat peripheral axotomy model of neuropathic pain. Proc Natl Acad Sci USA 2002; 99:8360-8365.
24. Mao J. Opioid-induced hyperalgesia. Pain Clin Updates 2008; XVI:1-4.
25. Célérier E, González JR, Maldonado R, et al. Opioid-induced hyperalgesia in a murine model of postoperative pain: role of nitric oxide generated from the inducible nitric oxide synthase. Anesthesiology 2006; 104:546-555.
26. Angst MS, Koppert W, Pahl I, et al. Short-term infusion of the mu-opioid agonist remifentanil in humans causes hyperalgesia during withdrawal. Pain 2003; 106:49-57.
27. Telfer P, Coen P, Chakravorty S, et al. Clinical outcomes in children with sickle cell disease living in England: a neonatal cohort study. Haematologica 2007; 92:905-912.
28. Platt OS. Prevention of stroke in sickle cell anaemia. N Engl J Med 2005; 353:2743.
29. Adams RJ, Brambilla D. Optimizing primary stroke prevention in sickle cell anaemia (STOP2) trial investigators. N Engl J Med 2005; 353:2769-2778.
30. Solomon L. Treatment and prevention of pain in adults with sickle cell disease. An educational void. Blood 2008; 111:997-1003.
31. Smith WR, Penberthy LT, Bouberg VE, et al. Daily assessment of pain in adults with sickle cell disease. Ass of Int Med 2008; 148:94-101.
32. Levenson JL, McClish DK, Dahman BA, et al. Depression and anxiety in adults with sickle cell disease; the PISCES project. Psychosom Med 2008; 70:192-196.
33. Citero VdA, Levenson JL, McClish DK, et al. The role of catastrophising in sickle cell disease: the PiSCES project. Pain 2007; 133:39-46.
34. McCLish DK, Penberthy LT, Bovbjerg VE, et al. Health related quality of life in sickle cell patients: the PiSCES project. Health Qual Life Outcomes 2005; 3:50-57.
35. Asnani MR, Lipps GE, Reid ME. Utility of WHOQOL-BREF in measuring quality of life in sickle cell disease. Health Qual Life Outcomes 2009; 7:75-81.
36. Howard J, Thomas VJ, Rawle HM. Pain management and quality of life in sickle cell disease. Exp Rev Pharmacoecon Outcomes Res 2009; 9:347-352.
37. Brandow AM, Brousseau DC, Pajewski NM, Panepinto JA. Vaso-occlusive painful events in sickle cell disease: impact on child well being. Pediatr Blood Cancer 2010; 54:92-97.
38. Aisuku IP, Smith WR, McClish DK, et al. Comparisons of high versus low emergency department utilizers in sickle cell disease. Ann Emerg Med 2009;53:587-593.
39. Wright K, Adeosun O. Barriers to effective pain management in sickle cell disease. Br J Nurs 2009; 18:158-161.
40. Charach S, Tenin ML, Moore RD, et al. Effect of HU on the frequency of painful crisis in SCA. N Engl J Med 1995; 332:1317-1322.
41. Steinberg MH, Barton F, Castro O, et al. Effect of HU on mortality and morbidity in adult SCA: notes and benefits up to 9 years of treatment. J Am Med Assoc 2003; 289:1645-1651.
42. Strouse JJ, Lanzkron S, Beach MC, et al. Hydroxyurea for sickle cell disease: a systematic review for efficacy and toxicity in children. Pediatrics 2008; 122:1332-1342.
43. Lanzkron S, Strouse JJ, Wilson R, et al. Systematic review: hydroxyurea in adults with sickle cell disease. Ann Int Med 2008; 148:939-945.
44. Rees DC, Olujohungbe A, Parker NE, et al. Guidelines for the management of acute painful crisis in sickle cell disease. Br J Haem 2003; 120:744-752.
45. Ferreira KASL, Kimura M, Teixeira MJ. The WHO analgesic ladder for cancer pain control, twenty years of use. How much pain relief does one get from using it? Support Care Cancer 2006; 14:1086-1093.
46. Dunlop R, Bennett KCLB. Pain management for sickle cell disease in children and adults. Cochrane Database Syst Rev 2006:CD003350.
47. Buchanan ID, Woodward M, Reed GW. Opioid selection during sickle cell pain crisis and its impact on the development of acute chest syndrome. Pediatr Blood Cancer 2005; 45:716-724.
48. van Beers EJ, van Tuijn CFJ, Nieuwkerk PT, et al. Patient-controlled analgesia versus continuous infusion of morphine during vaso-occlusive crisis in sickle cell disease, a randomized controlled trial. Am J Hematol 2007; 82:955-960.
49. Shaiova L, Wallenstein D. Outpatient management of sickle cell pain with chronic opioid pharmacotherapy. J Natl Med Assoc 2004; 96:984-986.
50. Payne R. Recognition and diagnosis of breakthrough pain. Pain Med 2007; 8:S3-S7.
51. O'Brien SH, Fan L, Kelleher KJ. Inpatient use of laxatives during opioid administration in children with sickle cell disease. Pediatr Blood Cancer 2010; 54:559-562.
52. Ahmedzai SH, Boland J. Constipation in people prescribed opioids. Clin Evid (Online) 2007; 2407.
53. Finkelstein Y, Schechter T, Garcia-Bournissen F, et al. Is morphine exposure associated with acute chest syndrome in children with vaso-occlusive crisis of sickle cell disease? A 6-year case-crossover study. Clin Ther 2007; 29: 2738-2743.
54. Richard RE. The management of sickle cell disease. Curr Pain Headache Rep 2009; 13:295-297.
55. Bartolucci P, Murr TE, Roudot-Thoravi F, et al. A randomised controlled clinical trial of ketoprofen for sickle cell disease vaso-occlusive crises in adults. Blood 2009; 114:3742-3747.
56. Okomu U, Meremikwu MM. Fluid replacement therapy for acute episodes of pain in people with sickle cell disease. Cochrane Database Syst Rev 2007:CD005406.
57. Marti-Carvajal AJ, Pena-Marti GE, Comunian-Carrasco G, Marti-Pena AJ. Interventions for treating painful sickle cell crisis during pregnancy. Cochrane Database Syst Rev 2009:CD006786.
58. A sickle crisis? Report of the National Confidential Enquiry into Patient Outcome and Death. May 2008.
59. Ahmedzai SH, Walsh D. Palliative medicine and modern cancer care. Semin Oncol 2000; 27:1-6.
60. Benjamin W, Swinson GI, Nagel R. Sickle cell anaemia day hospital: an approach for the management of uncomplicated crisis. Blood 2000; 95: 1130-1137.
61. Ware M, Hambleton I, Ochaya I, Serjeant GR. Day care management of sickle cell painful crisis in Jamaica: a model applicable elsewhere. Br J Haem 1999; 104:93-96.
62. Wright J, Bareford D, Wright C, et al. Day case management of sickle pain: 3 years experience in a UK sickle cell unit. Br J Haem 2004; 126:878-880.
63. Ahmedzai SH, Boland J. Opioids for chronic pain: molecular and genomic basis of actions and adverse effects. Curr Opin Support Palliat Care 2007; 1:117-125.
64. Dirks J, Fredensborg BB, Christensen D, et al.A randomized study of the effects of single-dose gabapentin versus placebo on postoperative pain and morphine consumption after mastectomy. Anesthesiology 2002; 97:560-564.